QNASL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7780038 | TEVA BRANDED PHARM | Dispensing apparatus with dosage counter |
Jan, 2027
(3 years from now) | |
| US10188811 | TEVA BRANDED PHARM | Nasal spray device |
Oct, 2031
(8 years from now) | |
Qnasl is owned by Teva Branded Pharm.
Qnasl contains Beclomethasone Dipropionate.
Qnasl has a total of 2 drug patents out of which 0 drug patents have expired.
Qnasl was authorised for market use on 23 March, 2012.
Qnasl is available in aerosol, metered;nasal dosage forms.
The generics of Qnasl are possible to be released after 21 October, 2031.
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 23 March, 2012
Treatment: NA
Dosage: AEROSOL, METERED;NASAL
More Information on Dosage
QNASL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic